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Cholesterol ester-laden macrophages, classically known as foam cells, are prominent features of atherosclerotic 
lesions and are widely recognized as an early cellular hall-
mark of atherosclerotic plaque development and lesion pro-
gression during coronary artery disease (CAD).1 Cholesterol 
efﬂux from cholesterol ester-laden macrophages within the 
artery wall, the ﬁrst and most likely rate-limiting step of the 
reverse cholesterol transport pathway, is critical in maintain-
ing intracellular cholesterol homeostasis.2 Circulating high-
density lipoprotein-cholesterol (HDLc) mass is inversely 
associated with incident cardiovascular disease risks, yet 
it is recognized to also serve as only a weak surrogate mea-
sure of HDL particle functionality in the reverse cholesterol 
transport process.2,3 Recent genetic studies question the causal 
relationship between low-circulating HDLc levels and height-
ened cardiovascular risks,4,5 and treatment strategies designed 
to raise HDLc levels have thus far not improved hard (ie, myo-
cardial infarction [MI], stroke, and death) outcomes.5–7 Despite 
these issues, there is a general belief, and certainly a hope, that 
measures of HDL particle function, beyond HDLc mass, may 
provide additive clinical prognostic value, as well as serve as a 
guide for therapeutics targeting apolipoprotein A1 (apoA1) or 
HDLc elevation and the reverse cholesterol transport process.8
See accompanying article on page 1449
Recent clinical studies aimed at assessing functional 
measures of HDL efﬂux activity have provided some hope 
for the concept that HDL functional measures may provide 
Objective—Diminished cholesterol efﬂux activity of apolipoprotein B (apoB)–depleted serum is associated with prevalent 
coronary artery disease, but its prognostic value for incident cardiovascular events is unclear. We investigated the 
relationship of cholesterol efﬂux activity with both prevalent coronary artery disease and incident development of major 
adverse cardiovascular events (death, myocardial infarction, or stroke).
Approach and Results—Cholesterol efﬂux activity from free cholesterol–enriched macrophages was measured in 2 case–
control cohorts: (1) an angiographic cohort (n=1150) comprising stable subjects undergoing elective diagnostic coronary 
angiography and (2) an outpatient cohort (n=577). Analysis of media from cholesterol efﬂux assays revealed that the 
high-density lipoprotein fraction (1.063<d<1.21) contained only a minority (≈40%) of [14C]cholesterol released, with 
the majority found within the lipoprotein particle–depleted fraction, where ≈60% was recovered after apolipoprotein 
A1 immunoprecipitation. Albumin immunoprecipitation recovered another ≈30% of radiolabeled cholesterol within this 
fraction. Enhanced cholesterol efﬂux activity from ATP-binding cassette transporter A1–stimulated macrophages was 
associated with reduced risk of prevalent coronary artery disease in unadjusted models within both cohorts; however, 
the inverse risk relationship remained signiﬁcant after adjustment for traditional coronary artery disease risk factors only 
within the outpatient cohort. Surprisingly, higher cholesterol efﬂux activity was associated with increase in prospective 
(3 years) risk of myocardial infarction/stroke (adjusted hazard ratio, 2.19; 95% conﬁdence interval, 1.02–4.74) and major 
adverse cardiovascular events (adjusted hazard ratio, 1.85; 95% conﬁdence interval, 1.11–3.06).
Conclusions—Heightened cholesterol efﬂux to apoB-depleted serum was paradoxically associated with increased 
prospective risk for myocardial infarction, stroke, and death. The majority of released radiolabeled cholesterol 
from macrophages in cholesterol efﬂux activity assays does not reside within a high-density lipoprotein particle. 
(Arterioscler Thromb Vasc Biol. 2013;33:1696-1705.)
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improved prognostic value or aid in monitoring HDL-targeted 
therapies. Using polyethylene glycol (PEG) as a convenient 
way to precipitate apolipoprotein B (apoB)–containing 
lipoproteins from serum leaving apoB-depleted serum as a 
surrogate for HDL functional measures, the collaborative 
research team of Drs Rader, Rothblatt, and colleagues 
recently reported that the cholesterol efﬂux measured from 
free cholesterol (FC)–enriched cultured macrophages to 
apoB-depleted serum as cholesterol acceptor was inversely 
associated with the history of CAD independent of HDLc 
levels.9 These seminal studies raise the exciting possibility 
that assays that monitor some form of HDL functionality, as 
opposed to HDLc mass, may provide important and clinically 
relevant information.
Despite the exciting recent ﬁndings suggesting cell-based 
measures of cholesterol efﬂux activity may provide enhanced 
prognostic value for risk of prevalent CAD, it should be noted 
that to date, there is no information available on the relation-
ship between macrophage cholesterol efﬂux activity measures 
from patient serum or plasma samples in large-scale clinical 
studies and incident cardiovascular event risks (eg, future risk 
for MI, stroke, or death). The use of cell-based measures in 
large-scale clinical studies is difﬁcult and requires extreme 
care to demonstrate reproducibility, linearity with respect to 
time and concentration of intended measures, and character-
ization of assumptions inherent in what is being measured. 
In the case of macrophage cholesterol efﬂux activity mea-
surements, it is fair to say that there is limited information 
reported on what activity measurements represent. For exam-
ple, remarkably, analysis of what compartment (eg, HDL par-
ticle versus alternatives) within the media which radiolabeled 
cholesterol tracer released from macrophages resides in is not 
available. In the present studies, we attempt to answer several 
of these questions and investigate the relationship of choles-
terol efﬂux activity measurement using apoB-depleted serum 
as cholesterol acceptor, and free radiolabeled cholesterol–
enriched macrophages as cholesterol donor, with both prev-
alent CAD and incident major adverse cardiovascular event 
(MACE) risks (heart attack, stroke, or death).
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
HDL Is a Minor Acceptor, and Lipid-Poor 
ApoA1 Forms a Signiﬁcant Acceptor, of 
[14C]Cholesterol in Media Recovered From 
Macrophage Cholesterol Efﬂux Assays
Recent macrophage cholesterol efﬂux studies using patient 
samples have used apoB-depleted serum as a surrogate for HDL 
function by precipitating apoB-containing particles with addi-
tion of PEG.9,10 In initial control studies, we, therefore, sought to 
examine 2 basic assumptions in macrophage cholesterol efﬂux 
assays using PEG-treated serum: (1) the efﬁciency of PEG 
induced apoB depletion and the impact of PEG treatment on 
HDL-related parameters and (2) the compartments within the 
media that macrophage derived [14C]cholesterol partitions into 
(ie, what proportion of released radiolabeled cholesterol actu-
ally resides in a particle that has buoyant density characteristics 
of an HDL particle or is associated with apoA1?). Multiple 
serum samples from outpatient cohort and healthy volunteer 
pools with normal HDLc and apoA1 levels (Table I in the 
online-only Data Supplement) or an angiographic cohort (to 
assess Lp(a) removal efﬁciency) were treated with PEG using 
established methods to form apoB-depleted serum10,11 and then 
analyzed. Quantitative removal of apoB and Lp(a) (essentially 
no detectable remaining) and quantitative recovery of apoA1 
(100.1±1.4%) and apoA2 (99.5±1.5%) were observed (Figure 
I in the online-only Data Supplement). In addition, reason-
ably complete recovery of HDLc (89.2±4.6%), the activity of 
the HDL-associated protein paraoxonase-1 (91.2±3.3%), and 
albumin (99.7±1.4%) were observed (Figure I in the online-
only Data Supplement). Separate control studies conﬁrmed the 
integrity of apoA1-containing HDL after PEG treatment (ie, 
that PEG treatment did not dissociate apoA1 from HDL) by 
showing that compared with control (vehicle-treated HDL), no 
signiﬁcant change in recovery of apoA1 in HDL versus the 
d>1.21 fraction was observed in samples before versus after
PEG treatment and repeat buoyant density ultracentrifugation
isolation of the HDL fraction (Table II in the online-only Data
Supplement). Collectively, these control studies showed rea-
sonable selectivity for both recovery of HDL-related param-
eters and complete removal of apoB and Lp(a)-containing
particles from apoB-depleted serum used for the macrophage
cholesterol efﬂux experiments.
We next sought to test the assumption that HDL serves as the 
major acceptor of radiolabeled cholesterol in the macrophage 
cholesterol efﬂux experiment, a prerequisite for claiming 
that macrophage efﬂux experiments serve as a surrogate 
measure of HDL functionality. For these studies, different 
serum samples (n=4) from healthy volunteer pools were again 
used (normal range HDLc and apoA1 for each sample; Table 
I in the online-only Data Supplement). Cultured RAW264.7 
macrophages were enriched with [14C]cholesterol as described 
under Methods in the online-only Data Supplement, and then 
apoB-depleted serum (1.4%) was used as cholesterol acceptor 
for macrophages under basal conditions, as well as after 
macrophage ATP-binding cassette transporter A1 (ABCA1) 
stimulation as described under Methods in the online-only 
Data Supplement. To separate the different lipoprotein 
fractions from recovered media for scintillation counting, we 
elected to use buoyant density isolation methods adjusting 
density stepwise with the low salt D2O/sucrose methodology, 
thus avoiding the chaotropic and high ionic strength issues 
associated with KBr.12 Figure 1A illustrates the distribution 
of recovered [14C]cholesterol in lipoprotein fractions within 
media from radiolabeled cholesterol–enriched macrophages 
under both basal (quiescent) state and on ABCA1 stimulation. 
Unexpectedly, the HDL fraction (1.063<d<1.21) harbored 
only a minority (≈42%) of [14C]cholesterol recovered in 
media from apoB-depleted serum under both conditions, 
with the majority of [14C]cholesterol (≈57%) found within 
the lipoprotein-depleted fraction. Further examination of the 
lipoprotein-depleted fraction within recovered media revealed 
that ≈60% of the radiolabeled cholesterol was associated with 
apoA1 and another ≈30% of radiolabeled cholesterol was 
associated with albumin (Figure 1A; Figures II and III in the 
online-only Data Supplement). Under basal condition, 38% of 
radiolabeled cholesterol was associated with apoA1 and 50% 
of radiolabeled cholesterol was associated with albumin. Thus, 
although HDL particles (1.063<d<1.21) are quantitatively 
only a minor acceptor of cholesterol in macrophage cholesterol 
efﬂux assays using apoB-depleted serum as cholesterol 
acceptor, the assays clearly do reﬂect apoA1 functionality 
in large part because 75% of total radiolabeled cholesterol 
recovered within media from the cultured macrophages was 
associated with apoA1.
Because of the somewhat surprising ﬁndings with human 
albumin (or an albumin-associated protein) serving as a 
quantitatively signiﬁcant acceptor of cholesterol under the 
cholesterol efﬂux experimental conditions used, we elected 
to perform further studies examining human serum albumin. 
As shown, although a signiﬁcantly poorer acceptor of cho-
lesterol than apoA1, human albumin, nonetheless, promoted 
cholesterol efﬂux in a dose-dependent fashion with broad lin-
ear range (Figure 1B; see Figure IV in the online-only Data 
Supplement for human serum albumin purity). Further, some-
what surprisingly, freshly isolated human serum albumin of 
purity (>98%) even greater than that of commercial sources 
showed up to 5-fold enhanced cholesterol acceptor activity. 
Although the speciﬁc activity for cholesterol acceptor activity 
for human albumin is much lower than that of apoA1 (≈280-
fold), because of its higher concentration, the predicted relative 
contribution of albumin to total cholesterol acceptor activity is 
approximately one-tenth that for apoA1 under normal plasma 
concentrations of albumin and apoA1 (Table III in the online-
only Data Supplement). Collectively, between apoA1 and 
albumin, 88±1.5% of radiolabeled cholesterol acceptor activ-
ity was accounted for under basal (nonstimulated) conditions 
and 90±2% with ABCA1 stimulation (Figure 1).
Further Characterization of Cellular 
Cholesterol Efﬂux Activity Assay
We next decided to examine the conditions used for 
cholesterol efﬂux activity assay using apoB-depleted serum 
as cholesterol acceptor. The cholesterol efﬂux activity assay 
used in the present studies is described in detail within 
Methods in the online-only Data Supplement. Figure 2 and 
Figures V and VI in the online-only Data Supplement provide 
assay characteristics and compare and contrast the assay 
used with different macrophage cell lines as well. Brieﬂy, 
the assay format used is illustrated in Figure 2A following 
methodology similar to that recently reported by Drs Rader, 
Rothblat, and colleagues (Figure 2A).9,10 Here, macrophages 
Figure 1. A, Distribution of radiolabeled choles 
terol found in various cholesterol acceptor serum 
fractions, RAW264.7 macrophages were incubated 
in the absence (basal) or presence (ATP-binding 
cassette transporter A1 [ABCA1] stimulated) of 
8-Br-cAMP as indicated with media containing
apoB-depleted serum (1.4% vol/vol) in cholesterol
efﬂux assays, as described in Methods in the online-
only Data Supplement. Radiolabeled cholesterol in
the indicated lipoprotein and lipoprotein-depleted
fractions (densities are indicated) after stepwise
buoyant density ultracentrifugation was quantiﬁed
as described in Methods in the online-only Data
Supplement. The distribution of radiolabeled-cho-
lesterol in lipoprotein-depleted media as assessed
after immunoprecipitation (IP) of apolipoprotein
A1 (apoA1) and albumin using anti-apoA1 mouse
monoclonal antibodies and antialbumin antibodies
as described in Methods in the online-only Data
Supplement. Results represent mean±SD for 4 sep-
arate experiments. B, (Left) Dose–response curves
of various sources of albumin (bovine and human
albumin from Sigma; fast performance liquid chro-
matography (FPLC) -isolated human serum albumin
[HSA] and FPLC-isolated and delipidated HSA) on
total cholesterol efﬂux in [3H]-cholesterol-loaded
RAW cells, and (right) isolated human apoA1. HDL
indicates high-density lipoprotein; LDL, low-density
lipoprotein; and VLDL, very low–density lipoprotein.
(typically RAW264.7 cells, but also J774A.1 cells where 
indicated) were labeled with [14C or 3H] cholesterol, and then 
after stimulation of ABCA1 expression, cholesterol efﬂux 
was measured by counting radiolabeled cholesterol recovered 
in media containing apoB-depleted serum as cholesterol 
acceptor. Although a proprietary acylCoA:cholesterol acyl 
transferase inhibitor used by Drs Rader, Rothblatt, and 
colleagues9,10 to prevent labeling of the cholesterol ester pool 
was not available for use in the present studies, under the 
conditions used, virtually all radiolabeled cholesterol loaded 
into the macrophages was found to be free (98.6±0.5%), 
with only 1.4±0.5% found within the cholesterol ester pool 
(Figure 2B). Further assay characterization studies conﬁrmed 
that the extent of cholesterol efﬂux activity measured from 
the FC-enriched macrophage efﬂux assay was linear over the 
time frame examined for both patient and healthy volunteer 
pooled samples under the conditions used (Figure 2C). 
Moreover, the ﬁnal apoB-depleted serum concentration used 
in media in the present studies (2%) was chosen to be close 
to that used by Rader, Rothblat, and colleagues (2.8% apoB-
depleted serum),9 despite the fact that total ABCA1-stimulated 
cholesterol efﬂux measured was within the curvilinear range 
of the graph examining ﬁnal serum concentration versus efﬂux 
measurement (Figure 2D). Figure 2E illustrates the intra batch 
reproducibility of cholesterol efﬂux activity measures using 
the FC-enriched macrophage cholesterol efﬂux assay with 
apoB-depleted serum as the cholesterol acceptor from murine 
macrophage RAW 264.7 cells, the preferred cell type used 
throughout the duration of the studies. We selected the murine 
macrophage RAW 264.7 cell for most studies because they 
demonstrated, in our hands, better growing characteristics, 
more reproducible cholesterol labeling, and improved 
reproducibility of ﬁnal efﬂux measures, likely related to 
improved adherence during wash steps. In addition, they 
show a modestly higher ABCA1-dependent efﬂux. However, 
because others have reported cholesterol efﬂux results using 
J774A.1 macrophages, as an additional control, we performed 
multiple control studies using macrophage cholesterol efﬂux 
assays using identical samples comparing results between 
murine macrophage RAW 264.7 cells and J774A.1 cells 
(ﬁrst set of comparisons; Figure V in the online-only Data 
Supplement). For these studies, apoB-depleted serum as 
cholesterol acceptor was used from a random sampling of 
subjects with documented CAD (n=36) and subjects without 
known CAD (n=27) to ensure that comparable efﬂux results 
were observed among both disease and nondisease subjects 
using these distinct macrophage cell lines. As noted, both total 
cholesterol efﬂux and ABCA1-dependent efﬂux activities 
measured between these 2 cell lines under the conditions used 
are highly correlated (for total cholesterol efﬂux: R=0.92, 
P<0.001, for all subjects; and R=0.95 and 0.89, P<0.001 for 
each, for CAD, and non-CAD). Additional control studies 
showed that under the conditions used, interassay variations 
for cholesterol efﬂux measures from plate to plate across 
different days (control samples of 8 per plate, 304 plates total) 
showed excellent reproducibility, with overall coefﬁcient of 
variation=5.3% throughout the study samples (Figure VI in 
the online-only Data Supplement).
Figure 2. Cholesterol efﬂux assay methodology and char-
acterization. A, General scheme of cholesterol efﬂux assay 
used. B, Autoradiogram and quantiﬁcation of cellular [14C] free 
cholesterol (FC) and [14C]cholesterylester (CE) found in [14C] 
cholesterol-loaded macrophage RAW cells. C, Time course 
of total cholesterol efﬂux to 2% serum, vol/vol (pool made 
from random sampling of the indicated number [n] of patient 
samples from the outpatient cohort and control serum pool, 
high-density lipoprotein-cholesterol [HDLc] 59 mg/dL, used). 
D, Dose-dependent efﬂux for total cholesterol from RAW264.7 
cells incubated with the indicated ﬁnal concentration (vol/vol) of 
apolipoprotein B (apoB)–depleted human serum as cholesterol 
acceptor. Serum pools with different HDLc levels as indicated 
were used. Values shown are an average of at least triplicate 
measurements. E, Intra batch apoB-depleted serum total cho-
lesterol efﬂux assay reproducibility was plotted as even plates 
vs odd plates in the same batch, Spearman correlation coefﬁ-
cient (R=0.89; P<0.001). ABCA1 indicates ATP-binding cassette 
transporter A1.
Conﬁrmation of Inverse Association Between 
Cholesterol Efﬂux Activity and Prevalent CAD 
Using ApoB-Depleted Serum as Cholesterol 
Acceptor From FC-Enriched Macrophages
The 2 study cohorts examined consisted of a total of 1727 
subjects with baseline clinical characteristics summarized in 
Table 1 according to cohorts and stratiﬁed by CAD status. As 
expected, subjects with CAD in either the angiographic cohort 
(cohort A) or the outpatient cohort (cohort B) had a greater 
prevalence of cardiovascular risk factors, such as diabetes 
mellitus, hypertension, smoking, elevated body mass index, 
and more frequent use of cardiovascular drugs. Subjects with 
CAD in both cohorts were more likely to have lower HDLc 
and apoA1 levels.
As expected, cholesterol efﬂux activity to apoB-depleted 
serum as cholesterol acceptor was inversely associated with 
risk of prevalent CAD in unadjusted models within both the 
stable angiographic cohort (unadjusted odds ratio, 0.60; 95% 
conﬁdence interval [CI], 0.42–0.85; P<0.01) and the outpa-
tient cohort (unadjusted odds ratio, 0.11; 95% CI, 0.06–0.20; 
P<0.01; Figure 3A and 3B). After adjustment for traditional 
risk factors, the inverse risk for prevalent CAD associated 
with elevated cholesterol efﬂux was attenuated within the 
stable angiographic cohort, but remained signiﬁcant within 
the outpatient cohort (Figure 3A and 3B).
Paradoxical Finding of Positive Association 
Between Enhanced Cholesterol Efﬂux 
Activity and Increased Risk for Incident 
Major Adverse Cardiovascular Events
We next examined the relationship between cholesterol efﬂux 
activity and incident risk for MACE (MI, stroke, or death) 
over the ensuing 3-year period after sample collection from 
subjects within the stable angiographic cohort, the only cohort 
with longitudinal outcome data. Surprisingly, subjects in the 
highest tertile of cholesterol efﬂux activity (relative to lowest 
tertile) showed a signiﬁcantly higher risk for incident nonfatal 
MI/stroke (unadjusted hazards ratio, 1.98; 95% CI, 1.04–3.78; 
P<0.05) and increased risk of incident MACE (unadjusted 
hazards ratio, 1.66; 95% CI, 1.07–2.58; P<0.05). These positive 
associations remained signiﬁcant after adjustments for traditional 
cardiovascular risk factors, with subjects having highest versus 
lowest tertile of cholesterol efﬂux still showing increased risk of 
incident MI/stroke (adjusted hazards ratio, 2.19; 95% CI, 1.02–
4.74; P<0.05) and incident MACE at 3 years (adjusted hazards 
ratio, 1.85; 95% CI, 1.11–3.06; P<0.05; Figure 4).
Table 1  Baseline Characteristics of the Case–Control Cohorts
Characteristics
Cohort A: Stable Angiographic Case–Control Cohort  
(n=1150)
Cohort B: Outpatient Case–Control Cohort
(n=577)
Controls (n=279)
Patients With 
Angiographically 
Conﬁrmed CAD 
(n=871) P Value Controls (n=431)
Patients With CAD 
(n=146) P Value
Age, y 72±6 61±11 <0.001 53±15 59±11 <0.001
Sex (men), % 54 67 <0.001 35 70 <0.001
DM, % 11 26 <0.001 6 30 <0.001
HTN, % 63 75 <0.001 26 66 <0.001
Smoking, % 54 69 <0.001 8 12 0.183
CAD, %  0 100 <0.001 0 100 <0.001
Total cholesterol, 
mg/dL
161 (145–187) 164 (142–188) 0.784 199 (171–229) 179 (130–214) <0.001
LDL, mg/dL 97 (82–113) 96 (79–117) 0.975 117 (94–145) 89 (61–131) <0.001
HDL, mg/dL 39 (32–46) 33 (28–39) <0.001 53 (45–65) 44 (36–52) <0.001
Triglycerides, mg/dL 89 (69–128) 131 (96–189) <0.001 112 (79–162) 136 (82–214) 0.003
Albumin, g/dL 3.9 (3.7–4.1) 4.1 (3.9–4 3) <0.001 4.4 (4.2–4.6) 4.5 (4.2–4.7) 0.001
apoA1, mg/dL 125 (107–138) 116 (105–132) <0.001 149 (131–169) 136 (121–146) <0.001
apoA2, mg/dL 32 (28–35) 33 (29–36) 0.01 38 (34–43) 33 (27–38) <0.001
Framingham ATP III 
risk score
9 (8–12) 8 (6–11) <0.001 4 (2–8) 6 (2–8) 0.122
BMI, kg/m2 26.8 (24–31.4) 28.7 (26–32.2) <0.001 29.4 (24.7–34.1) 31.2 (27.4–34.1) 0.036
Baseline medications, %
ACE inhibitors 41 53 0.001 5 37 <0.001
β-Blockers 43 72 <0.001 5 56 <0.001
 Statin 32 71 <0.001 11 59 <0.001
 Aspirin 58 83 <0.001 50 60 0.138
ACE indicates angiotensin-converting enzyme; apo, apolipoprotein; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; HDL, high-density 
lipoprotein; HTN, hypertension; and LDL, low-density lipoprotein.
The observation of higher cholesterol efﬂux being 
associated with higher incident MACE risks was surprising. 
We, therefore, examined the relationships between the 
cholesterol efﬂux activity measured and HDL-related 
parameters, as well as other blood-based assays. As expected, 
strong and statistically signiﬁcant positive associations were 
noted between cholesterol efﬂux activity measured and levels 
of HDLc, apoA1, and apoA2 within both the angiographic 
cohort and the outpatient cohort (Table 2). Further, the 
magnitude of the observed positive associations was similar 
to that previously reported using similar cholesterol efﬂux 
activity assays with apoB-depleted serum as cholesterol 
acceptor.9 In a further effort to understand the associations 
observed between cholesterol efﬂux measures and lipoprotein-
related parameters, we stratiﬁed each cohort by the presence 
versus absence of cardiovascular phenotypes (eg, CAD versus 
non-CAD for both cohorts; and also presence versus absence 
of incident MI/stroke or MACE in the stable angiographic 
cohort where longitudinal outcomes were available). These 
analyses still showed within each subgroup the anticipated 
positive association between enhanced cholesterol efﬂux 
measurement and enhanced level of HDLc, and HDL-related 
lipoproteins apoA1 and apoA2 (Table IV in the online-only 
Data Supplement). Thus, the cholesterol efﬂux measures 
performed all showed positive associations, as expected, with 
HDL and HDL-related lipoprotein measures within the entire 
cohort and within the different subgroups.
In an additional series of analyses, we also thought it rea-
sonable to examine whether traditional cardiovascular risk 
factors associate with prevalent and incident cardiovascular 
risks as anticipated in the stable angiographic cohort given 
the unanticipated ﬁndings. Comparison of several recognized 
cardiovascular risk factors and the cholesterol efﬂux measures 
performed versus risk for prevalent CAD or incident (3 years) 
MACE in multiple logistic regression models is shown in 
Figure VII in the online-only Data Supplement. As expected, 
diabetes mellitus, hypertension and smoking were each asso-
ciated to increased risk of CAD and showed strong trend 
toward increased risk of MACE, whereas HDLc level was 
inversely associated with prevalent risk of CAD and showed 
trend toward negative association with incident MACE risk. 
Low-density lipoprotein-cholesterol in this cohort was not 
associated with either CAD or MACE risk, a ﬁnding observed 
previously and commonly seen among highly medicated 
cohorts. Remarkably, total cholesterol efﬂux activity (here 
modeled as continuous variable) showed strong trend toward 
increased risk of CAD and signiﬁcant positive association 
with incident risk of MACE at 3 years and with point estimate 
for MACE risk similar in magnitude to that observed for dia-
betes mellitus, hypertension, and smoking (Figure VII in the 
online-only Data Supplement).
Discussion
This study was initially intended to answer some presum-
ably simple questions about cellular cholesterol efﬂux activ-
ity measures and incident risks for cardiovascular disease. In 
the end, however, it has generated more questions than it has 
answered. First and foremost perhaps is the question of what 
Figure 3. Forrest plot indicating prevalent coronary artery 
disease (CAD) risk in stable angiographic and outpatient 
cohorts. Apolipoprotein B–depleted serum as the choles-
terol acceptor in cholesterol efﬂux assays. A, Relationship 
between total cholesterol efﬂux activity and prevalent 
CAD plotted from low to high tertiles in the angiographic 
cohort. B, Outpatient cohort. Multilogistic regression model 
included adjustments for age, sex, smoking, diabetes mel-
litus, hypertension, low-density lipoprotein-cholesterol, and 
high-density lipoprotein-cholesterol levels. Patient sample 
size (n) is indicated. The 5% to 95% conﬁdence interval (CI) 
is indicated by line length.
Figure 4. Forrest plot indicating incident cardiovascu-
lar risks for the stable angiographic cohort. Relationship 
between total cholesterol efﬂux activity and incident (3 
years) risk of myocardial infarction (MI)/stroke (left) or 
major adverse cardiovascular event (MACE; MI, stroke, or 
death; right) plotted from low to high tertiles. Multilogistic 
regression model included either no adjustments or adjust-
ments for age, sex, smoking, diabetes mellitus, hyperten-
sion, low-density lipoprotein-cholesterol, and high-density 
lipoprotein-cholesterol levels as indicated. The 5% to 95% 
conﬁdence interval (CI) is indicated by line length.
exactly do radiolabeled cholesterol efﬂux activity assays as 
recently reported and performed herein actually measure?
One simple yet key ﬁnding is the observation that the 
majority of radiolabeled FC tracer released from cholesterol-
enriched macrophages does not reside within the HDL particle, 
but rather, within the lipoprotein-depleted fraction after buoy-
ant density removal of lipoprotein particles. This partitioning 
was initially observed with traditional KBr-dependent buoy-
ant density isolation of lipoprotein fractions from cell efﬂux 
assay media (not shown). Because of concerns of lipoprotein 
composition alterations and release of exchangeable lipopro-
teins from particles under the high salt concentrations that 
exist during such isolation procedures, we, therefore, opted to 
repeat all studies using the low salt, D2O/sucrose method for 
lipoprotein ultracentrifugation isolations to minimize apoA1 
shedding from the HDL particle. Despite this precaution, we 
still observed the same surprising results that the majority of 
counts reside within the lipoprotein-depleted fraction (Figure 
1). Further analyses of the lipoprotein-depleted media fraction 
remaining after removal of lipoproteins revealed ≈60% of the 
counts are associated with apoA1, with a full 40% remaining 
despite quantitative removal of apoA1. Thus, ≈75% of radio-
labeled cholesterol interacts with apoA1 as cholesterol accep-
tor within media, but this observation also begs the question 
of what the other major cholesterol acceptors are during the 
cholesterol efﬂux activity assay.
To investigate which other proteins might participate 
in cholesterol acceptance in these assays, we considered 
other exchangeable lipoproteins (eg, apoE, apoCs, etc) or 
amphipathic proteins, such as serum amyloid A, because 
other exchangeable lipoproteins13 have been reported to also 
be capable of serving as cholesterol acceptors, although their 
contribution within the serum compartment remains to be 
established. However, early on we performed immunoprecipi-
tation studies for human albumin and observed that the vast 
majority of residual counts in the lipoprotein-depleted media, 
not counting the apoA1 contribution, could be accounted for 
by albumin immunodepletion, hence we pursued this line of 
inquiry in the present studies. We suspect signiﬁcant propor-
tions of these counts bind directly to albumin, but also recog-
nize that the albumin-associated proteome is vast, and think it 
prudent to note that we cannot exclude the possibility that trace 
levels of ≥1 albumin-associated (lipo)proteins with choles-
terol acceptor activity (especially if comparable with apoA1, 
which is ≈300-fold higher than albumin per gram of protein) 
may coimmunoprecipitate with the albumin, and thus theoreti-
cally could contribute to a portion of the cholesterol acceptor 
activity attributed to albumin. Our data with highly puriﬁed 
albumin with no visible-associated lipoproteins clearly show 
that albumin itself can promote cholesterol efﬂux, albeit at 
a far poorer speciﬁc activity than apoA1. It is also interest-
ing to note that other investigators recently noted recombi-
nant human albumin can serve as cholesterol acceptor and 
showed that several site-speciﬁc mutations can signiﬁcantly 
reduce the cholesterol acceptor activity of the protein.14 It is 
important to note that we observed different sources of human 
serum albumin had signiﬁcantly different cholesterol acceptor 
activity, suggesting that a conformationally intact albumin is 
needed for full cholesterol acceptor activity.
Another question the present studies raise is whether 
apoB-depleted serum even represents a reasonable estimate 
of cholesterol acceptor activity within the vascular compart-
ment. We chose to use apoB-depleted serum in the present 
studies because the seminal studies of Khera et al9 suggested 
that it might serve as a good functional measure of HDL and 
might predict incident CVD risks. However, apoB-containing 
lipoprotein particles are known acceptors of cholesterol,15,16 
and red blood cells represent a dynamic pool for cholesterol 
exchange and participates in reverse cholesterol transport.17 
Recognition that HDL particles serve as only a minor accep-
tor (≈40%) of radiolabeled cholesterol within apoB-depleted 
serum during the currently reported cholesterol efﬂux activ-
ity assay provides rationale to question whether such assays 
serve as a surrogate measure for HDL functional activity. As 
discussed below, the assay may reﬂect even more importantly 
the lipid-poor apoA1 pool and its relationship to incident 
MACE risk.
Perhaps the most surprising ﬁnding within this study is how 
complex the relationship is between cellular cholesterol efﬂux 
measurements and cardiovascular phenotypes (atheroscle-
rotic plaque development, which is related to prevalent CAD, 
versus plaque vulnerability-associated phenotypes, such as 
incident MI/stroke or MACE risks). Review of the literature 
reveals that prior studies have suggested possible complica-
tions to the simplistic view that measures of cholesterol efﬂux 
activity are inversely related to cardiac risks. For example, 
de Vries et al18 reported that studies using a ﬁbroblast cell 
line in a small nested case–control design for cardiovascu-
lar disease observed that cholesterol efﬂux measures were 
not signiﬁcantly correlated with cardiovascular events. In a 
different study by Chirinos et al,19 cholesterol efﬂux activity 
was measured in vitro using cultured human skin ﬁbroblasts 
by incubation with serum from subjects undergoing coronary 
angiography. Efﬂux in this assay was not measured by radiola-
beled cholesterol liberated into media, but rather, by the ability 
of serum to deplete the intracellular cholesterol pool available 
for esteriﬁcation by the acylCoA:cholesterol acyl transfer-
ase reaction (ie, higher efﬂux was indicated by lower cellu-
lar acylCoA:cholesterol acyl transferase activity). Decreased 
cellular acylCoA:cholesterol acyl transferase activity in this 
small case–control study was independently positively asso-
ciated with increased risk of MACE and death,19 similar to 
the results observed in the present studies. In another small 
study, cholesterol efﬂux to plasma from hypertriglyceridemic 
Table 2. Correlation Coefﬁcients Between High-Density 
Lipoprotein/Lipoprotein-Related Variables and Apolipoprotein 
B–Depleted Serum Total Cholesterol Efﬂux Cholesterol Efﬂux
ApoB-Depleted Serum Total Cholesterol Efﬂux
Angiographic Cohort 
(n=1150) Outpatient Cohort (n=577)
HDL cholesterol 0.45 (P<0.001) 0.52 (P<0.001)
apoA1 0.56 (P<0.001) 0.61 (P<0.001)
apoA2 0.45 (P<0.001) 0.55 (P<0.001)
Albumin 0.04 (P=0.19) −0.05 (P=0.236)
apo indicates apolipoprotein; and HDL, high-density lipoprotein.
patients with diabetes mellitus, subjects with a CAD risk 
equivalent, was increased compared with efﬂux to plasma 
from those with normotriglyceridemic or healthy controls.20 
Finally, in a recent case–control study of obese subjects, plas-
mas from insulin-resistant individuals showed greater cho-
lesterol efﬂux activity compared with subjects demonstrating 
insulin sensitivity.21
Each of the above studies was small, used alternative cell 
types, and alternative cholesterol acceptors (whole serum, or 
plasma, and not apoB-depleted serum). They also looked at 
different aspects of cholesterol efﬂux (either tracer studies 
or cellular cholesterol mass in 1 case). But all underscore the 
large number of possible assays and methodologies, and the 
possibility that the selection of the cellular cholesterol efﬂux 
system may be a critical determinant in performance of such 
ex vivo HDL functionality assays. One strength of the present 
studies is it large size, and the efforts made to perform assays 
under conditions that closely mirror those of the seminal ﬁnd-
ings of Khera et al.9 It is worth noting that using such an assay, 
and both study design and patient populations similar to that 
recently reported,9 we too observed that cholesterol efﬂux 
activity using apoB-depleted serum as cholesterol acceptor 
and FC-labeled macrophages was inversely associated (unad-
justed) with prevalent CAD status in both cohorts examined. 
We also observed the anticipated positive associations between 
cholesterol efﬂux measures and levels of HDLc, and HDL-
related lipoproteins (apoA1 and apoA2) within both cohorts 
and within subjects with versus without various cardiovascu-
lar disease phenotypes. Two important differences between 
this study and that recently reported9 are the selection crite-
rion of patient cohort used and the distribution of cholesterol 
efﬂux values within each population. In the previous report,9 
the majority of the patients were a small subset selected from 
2 much larger clinical studies and assigned to either case 
or control status. In contrast, the main results reported here 
(angiographic cohort) were obtained from sequential partici-
pants enrolled in the study GeneBank.22–26 The distribution of 
values for cholesterol efﬂux was much broader in the case–
control study reported by Khera et al,9 with max/min ratio 
equal to 8. In contrast, the sequential subjects from the angio-
graphic cohort studied herein demonstrated a max/min ratio 
for cholesterol efﬂux measures equal to only 3. This narrower 
distribution of values likely contributes to the loss of statisti-
cal signiﬁcance in the relationship between CAD prevalence 
and cellular cholesterol efﬂux after adjustment for other risk 
factors in the angiographic cohort. Notably, in the sequential 
outpatient cohort used in this study, we also observed a strong 
inverse correlation that remained signiﬁcant after adjustment 
for traditional risks factors between cellular cholesterol efﬂux 
measured using apoB-depleted serum as cholesterol accep-
tor and the prevalence of CAD. Consequently, the strength 
of relationship between prevalence of CAD and cholesterol 
efﬂux seems to be cohort dependent.
However, a totally unanticipated observation was the posi-
tive association between increased cellular cholesterol efﬂux 
measures and increased prospective risks for cardiovascular 
events (MI/stroke and MACE). Control studies conﬁrmed that 
macrophage cell type did not have signiﬁcant effect on the 
cholesterol efﬂux measures because comparisons between 
J774A.1 and RAW264.7 macrophages revealed highly cor-
related assay values among both patients and healthy control 
subjects alike (Figure V in the online-only Data Supplement). 
In a separate set of control studies comparing the 2 distinct 
macrophage cell lines, similar results were observed—here 
for apoB-depleted serum from 80 random subjects to com-
pare total and cAMP-independent cholesterol efﬂux elicited 
from either RAW 264.7 or J774A.1 cells (Figures VIII and 
VIIII in the online-only Data Supplement). Under the condi-
tions used, the absolute magnitude of the cAMP-independent 
efﬂux was identical for both cell lines within the accuracy of 
the assay and highly correlated (R=0.96; P<0.001). Although 
the magnitude of the total cholesterol efﬂux in the presence 
of cAMP was almost 2× higher for the RAW264.7 than for 
J774A.1 cells, the correlation of results between those cell 
lines remained excellent (R=0.91; P<0.001). The major dif-
ference between those 2 cell lines was the magnitude, both 
absolute and relative, for the cAMP-dependent cholesterol 
efﬂux. Results obtained with the J774A.1 cell line, described 
above, are remarkably consistent with those published10 in a 
methodological characterization of the assay that was subse-
quently used to characterize the relationship between preva-
lence of CAD and cholesterol efﬂux.9 This is true with regard 
to both absolute magnitude of the cholesterol efﬂux and minor 
contribution of the cAMP-dependent component to the total 
cholesterol efﬂux (Figure 110). Further, it should be noted that 
in separate analyses, the relationship between apoA1 levels 
and incident MACE risk within the stable angiographic cohort 
showed the anticipated inverse association, with subjects in 
the lowest 5 percentile (<89 mg/dL) versus the highest 5 per-
centile (≥153 mg/dL) of apoA1 values having a frequency of 
experiencing MACE (3 years) of 22.2% versus 10.2%, respec-
tively. Thus, on the whole, congruent results were observed 
with prior published studies using apoB-depleted serum and 
the present studies, and the anticipated inverse relationship 
between apoA1 levels and incident MACE risk.
Thus, perhaps the paradoxical relationship observed 
between higher cholesterol efﬂux and higher prospective 
risk for cardiovascular events in the present study is not 
paradoxical at all. The name cholesterol efﬂux activity con-
jures images of an active function of the target cell, pumping 
cholesterol into the media for a passively waiting acceptor. 
Perhaps the name of the assay itself is somewhat of a misno-
mer. One interpretation of the present observations is that the 
capacity of the media (in this case, apoB-depleted serum) to 
accept cholesterol itself is an equally relevant measure and is 
related to a subject’s propensity to develop vulnerable plaque 
(ie, incident cardiovascular event risk). Indeed, enhanced 
cholesterol acceptor capacity within the apoB-depleted 
serum fraction was positively associated with increased 
3-year incident risks for MI/stroke and MACE (MI/stroke or
death). It also begs mentioning that there may be a disconnect
between cholesterol efﬂux measures and the development of
atherosclerotic plaque, versus the development of vulnerable
plaque. Further examination of these relationships is clearly
warranted and in alternative types of patient populations. It
should also be noted that the magnitude of the positive asso-
ciation between the efﬂux measures made and prospective
risks for MI, stroke, or death in the present studies was quite
large and signiﬁcant. Moreover, it remained signiﬁcant with 
minimal diminution after adjustments for traditional cardio-
vascular risk factors (Figure 4; Figure VII in the online-only 
Data Supplement).
The present analyses are, to our knowledge, the ﬁrst larger 
scale prospective study that determines the association of cel-
lular cholesterol efﬂux activity using apoB-depleted serum as 
cholesterol acceptor with both prevalent CAD disease risks 
and future risks for experiencing MACE. We speculate that 
ABCA1-dependent cholesterol efﬂux pathway may play 
a key role in these apparently paradoxical results because 
using apoB-depleted serum as cholesterol acceptor, ABCA1-
dependent cholesterol efﬂux activity represents a signiﬁcant 
proportion of total efﬂux activity measured under the condi-
tions used (where ABCA1 levels were stimulated). The use of 
alternative efﬂux activity assays, whether following choles-
terol mass or alternative cholesterol efﬂux pathways, may pro-
vide different results. The relationship between such analyses 
and incident risks for MACE remains to be reported. Smaller, 
lipid-poor pre-β-HDL particles, named for their electropho-
retic behavior and not for their buoyant density, are reported 
to be primary acceptors of cholesterol from the ABCA1 trans-
porter in macrophages.3,11,27–29 Previous studies have reported 
that ABCA1-dependent cholesterol efﬂux is correlated with 
the concentration of pre-β-HDL.10 Further, pre–β-HDL is 
reportedly positively correlated with coronary heart disease 
and history of MI.30–32 These latter studies are not cellular 
cholesterol efﬂux activity measures, but rather, quantify lipid-
poor apoA1 forms, or in 1 case, cholesterol exchange into a 
low molecular weight form apoA1-containing species as mea-
sured by an ultraﬁltration-isotope dilution technique.30–32 To 
our knowledge, what proportion, if any, of pre-β-HDL par-
ticles have density of an HDL particle (between 1.063 and 
1.21) is unknown. The majority of radiolabeled cholesterol 
released to the media during the current cholesterol efﬂux 
measurements, whether using basal or ABCA1-stimulated 
macrophages, remained in the lipoprotein-depleted compart-
ment, although a signiﬁcant portion of the counts within the 
lipoprotein-depleted fraction was associated with apoA1. It is 
conceivable that subject sera with greatest ability to accept 
cholesterol may contain increased levels of lipid poor and not 
HDL-associated apoA1 or other lipoproteins, although this 
remains speculative and merits further investigation. Indeed, 
lipoprotein subfractionation studies were not performed in the 
present cohort and is another limitation of the present studies. 
Whether such measures track with cholesterol efﬂux measures 
with apoB-depleted serum as cholesterol acceptor, or incident 
MACE risk, is a question that requires further investigation. 
Examination of the correlations between cholesterol efﬂux 
measures among the different subjects in the cohorts exam-
ined demonstrates an interesting trend in all subcohorts (Table 
II in the online-only Data Supplement) for decreased strength 
of the correlation between the cholesterol efﬂux measured 
and the HDL-related parameter (HDLc, apoA1, and apoA2) 
in disease versus nondisease subgroups, suggesting a weaker 
(as a result of dysfunctional component?) association during 
cardiovascular disease. It is noteworthy that we have shown 
that oxidative modiﬁcation of HDL by the myeloperoxi-
dase system leads to functional impairment (loss of ABCA1 
cholesterol efﬂux activity) and loss of lipid binding function, 
in general, for the oxidized apoA1.33
Recent large-scale genetic studies in humans raise doubts 
as to whether genetic variants that control circulating HDLc 
concentrations are causally linked to prevalent cardiovascu-
lar disease risks and atherosclerotic heart disease pathogen-
esis.4 These results, coupled with the recognition that HDLc 
mass is not a reliable index of cholesterol ﬂux through the 
HDL particle/pathway, have led for the search for assays that 
both gauge HDL functions and may serve as aids in guiding 
HDL and apoA1-targeted therapies currently under inves-
tigation. The present results challenge several established 
views regarding the cellular cholesterol efﬂux activity assay 
and point for the need of additional studies to better under-
stand both what these assays are monitoring and how best 
to monitor the many distinct functions of HDL in a practi-
cal manner amenable to translation into clinical studies, and 
preferably, clinical practice. One last ﬁnding of the present 
studies that is worth highlighting is the positive association 
between measured cellular cholesterol efﬂux and incident 
MACE risk observed. This relationship was quite strong 
and remained signiﬁcant after multivariate adjustments. The 
biological process(es) it measures seems to track with inci-
dent MACE risk. The genetic variants and key biochemical 
determinants that control cholesterol acceptor capacity of a 
subject (at least for apoB-depleted serum) warrant further 
investigation, as do further studies examining the effect of 
using alternative cholesterol acceptors, such as whole serum.
Acknowledgments
We thank Michael Pepoy, Barbara Sullivan, Sarah Neale, Alan 
Pratt, Thomas Tallant, Jiannong Dai, Haihong Guo, Desire 
Riedy, and Alys Jordan for their assistance.
Sources of Funding
This research was supported by National Institutes of Health grant 
P01HL098055 and by the Fondation LeDucq. GeneBank has been 
supported by National Institutes of Health grants P01HL076491, 
R01HL103866, R01HL103931, and P20HL113452 and the 
Cleveland Clinic Clinical Research Unit of the Case Western Reserve 
University The Clinical and Translational Science Collaborative 
(UL1TR 000439-06). Dr Hazen is also partially supported by a gift 
from the Leonard Krieger Foundation.
Disclosures
Dr Tang has previously received research grant support from Abbott 
Laboratories. Drs Hazen and Smith report being listed as coinventors on 
pending and issued patents held by the Cleveland Clinic relating to car-
diovascular diagnostics and therapeutics. Dr Hazen reports having been 
paid as a consultant or speaker for the following companies: Abbott 
Diagnostics, Cleveland Heart Laboratory, Esperion, Lilly, Liposcience 
Inc, Merck & Co, Inc, and Pﬁzer Inc. Dr Hazen reports receiving research 
funds from Abbott, Cleveland Heart Laboratory, Liposcience Inc, and 
Pﬁzer Inc. Dr Hazen reports having the right to receive royalty pay-
ments for inventions or discoveries related to cardiovascular diagnostics 
or therapeutics from the companies shown below: Abbott Laboratories, 
Inc, Cleveland Heart Laboratory, Esperion, Frantz Biomarkers, LLC, 
Liposcience Inc, and Siemens. Dr Smith reports having been paid as 
a consultant and receiving research funds from for Esperion. Dr Smith 
reports having the right to receive royalty payments for inventions or 
discoveries related to cardiovascular diagnostics or therapeutics from 
Cleveland Heart Laboratory and Esperion. Dr Mosior is an employee of 
Eli Lilly and Company and owns Eli Lilly company stock.
References
1. Maxﬁeld FR, Tabas I. Role of cholesterol and lipid organization in disease. 
Nature. 2005;438:612–621.
2. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein 
J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat 
GH, Tall AR, Yvan-Charvet L. Cholesterol efﬂux and atheroprotection:
advancing the concept of reverse cholesterol transport. Circulation. 
2012;125:1905–1919.
3. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardio-
vascular disease: atherogenic and atheroprotective mechanisms. Nat Rev
Cardiol. 2011;8:222–232.
4. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL choles-
terol and risk of myocardial infarction: a mendelian randomisation study.
Lancet. 2012;380:572–580.
5. Boden WE, Probstﬁeld JL, Anderson T, Chaitman BR, Desvignes-Nickens 
P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with 
low HDL cholesterol levels receiving intensive statin therapy. N Engl J
Med. 2011;365:2255–2267.
6. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P,
Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH,
Deanﬁeld JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT
Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE)
Investigators. Effect of ACAT inhibition on the progression of coronary
atherosclerosis. N Engl J Med. 2006;354:1253–1263.
7. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan
WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM;
ILLUSTRATE Investigators. Effect of torcetrapib on the progression of
coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316.
8. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the
HDL cholesterol hypothesis? Nat Med. 2012;18:1344–1346.
9. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri
K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER,
Rothblat GH, Rader DJ. Cholesterol efﬂux capacity, high-density lipopro-
tein function, and atherosclerosis. N Engl J Med. 2011;364:127–135.
 10. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader
DJ, Rothblat GH. The ability to promote efﬂux via ABCA1 determines the 
capacity of serum specimens with similar high-density lipoprotein choles-
terol to remove cholesterol from macrophages. Arterioscler Thromb Vasc 
Biol. 2010;30:796–801.
 11. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer
EJ, Rothblat GH. Differential effects of HDL subpopulations on cel-
lular ABCA1- and SR-BI-mediated cholesterol efﬂux. J Lipid Res. 
2005;46:2246–2253.
 12. Ståhlman M, Davidsson P, Kanmert I, Rosengren B, Borén J, Fagerberg
B, Camejo G. Proteomics and lipids of lipoproteins isolated at low salt
concentrations in D2O/sucrose or in KBr. J Lipid Res. 2008;49:481–490.
 13. Travis AJ, Kopf GS. The role of cholesterol efﬂux in regulating the
fertilization potential of mammalian spermatozoa. J Clin Invest. 
2002;110:731–736.
 14. Ha JS, Ha CE, Chao JT, Petersen CE, Theriault A, Bhagavan NV. Human 
serum albumin and its structural variants mediate cholesterol efﬂux from
cultured endothelial cells. Biochim Biophys Acta. 2003;1640:119–128.
 15. Brown MS, Goldstein JL. The receptor model for transport of cholesterol
in plasma. Ann N Y Acad Sci. 1985;454:178–182.
 16. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC
transporters, and cholesterol efﬂux: implications for the treatment of ath-
erosclerosis. Cell Metab. 2008;7:365–375.
 17. Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD. Red blood cells 
play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 
2012;32:1460–1465.
 18. de Vries R, Groen AK, Dullaart RP. Cholesterol efﬂux capacity and ath-
erosclerosis. N Engl J Med. 2011;364:1473–1474; author reply 1474.
 19. Chirinos JA, Zambrano JP, Chakko S, Schob A, Goldberg RB, Perez G,
Mendez AJ. Ability of serum to decrease cellular acylCoA:cholesterol
acyl transferase activity predicts cardiovascular outcomes. Circulation. 
2005;112:2446–2453.
 20. de Vries R, Groen AK, Perton FG, Dallinga-Thie GM, van Wijland MJ,
Dikkeschei LD, Wolffenbuttel BH, van Tol A, Dullaart RP. Increased
cholesterol efﬂux from cultured ﬁbroblasts to plasma from hypertriglyc-
eridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid
transfer protein and cholesterol esteriﬁcation. Atherosclerosis. 2008;196: 
733–741.
 21. Nestel P, Hoang A, Sviridov D, Straznicky N. Cholesterol efﬂux from mac-
rophages is inﬂuenced differentially by plasmas from overweight insulin-
sensitive and -resistant subjects. Int J Obes (Lond). 2012;36:407–413.
 22. Brennan ML, Reddy A, Tang WH, Wu Y, Brennan DM, Hsu A, Mann SA, 
Hammer PL, Hazen SL. Comprehensive peroxidase-based hematologic
proﬁling for the prediction of 1-year myocardial infarction and death.
Circulation. 2010;122:70–79.
 23. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J,
Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation
links inﬂammation, smoking, uremia and atherogenesis. Nat Med. 
2007;13:1176–1184.
 24. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted metabolo-
mic evaluation of arginine methylation and cardiovascular risks: potential 
mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb 
Vasc Biol. 2009;29:1383–1391.
 25. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished
global arginine bioavailability and increased arginine catabolism as
metabolic proﬁle of increased cardiovascular risk. J Am Coll Cardiol. 
2009;53:2061–2067.
 26. Wang Z, Klipfell E, Bennett BJ, et al. Gut ﬂora metabolism of phosphati-
dylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.
 27. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, 
Schaefer EJ. High-density lipoprotein subpopulation proﬁle and coronary 
heart disease prevalence in male participants of the Framingham Offspring 
Study. Arterioscler Thromb Vasc Biol. 2004;24:2181–2187.
 28. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, Parks JS. Minimal
lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact 
with ABCA1. Arterioscler Thromb Vasc Biol. 2007;27:1828–1836.
 29. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F,
Kovanen PT. Depletion of pre-beta-high density lipoprotein by human
chymase impairs ATP-binding cassette transporter A1- but not scavenger
receptor class B type I-mediated lipid efﬂux to high density lipoprotein. J 
Biol Chem. 2004;279:9930–9936.
 30. Kane JP, Malloy MJ. Prebeta-1 HDL and coronary heart disease. Curr 
Opin Lipidol. 2012;23:367–371.
 31. Guey LT, Pullinger CR, Ishida BY, O’Connor PM, Zellner C, Francone
OL, Laramie JM, Naya-Vigne JM, Siradze KA, Deedwania P, Redberg
RF, Frost PH, Seymour AB, Kane JP, Malloy MJ. Relation of increased
prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. 
Am J Cardiol. 2011;108:360–366.
 32. de Vries R, Perton FG, van Tol A, Dullaart RP. Carotid intima media thick-
ness is related positively to plasma pre ß-high density lipoproteins in non-
diabetic subjects. Clin Chim Acta. 2012;413:473–477.
 33. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, Kinter
M. Localization of nitration and chlorination sites on apolipoprotein A-I
catalyzed by myeloperoxidase in human atheroma and associated oxida-
tive impairment in ABCA1-dependent cholesterol efﬂux from macro-
phages. J Biol Chem. 2005;280:38–47.
Signiﬁcance
Despite observing diminished cholesterol efﬂux activity of apolipoprotein B–depleted serum is associated with prevalent coronary artery 
disease, heightened cholesterol efﬂux to apolipoprotein B–depleted serum was paradoxically associated with increased prospective risk 
for myocardial infarction, stroke, and death. The majority of released radiolabeled cholesterol from macrophages in cholesterol efﬂux 
activity assays does not reside within an high-density lipoprotein particle, although 75% was associated with apolipoprotein A1. The pres-
ent studies imply that subjects with apolipoprotein B–depleted sera with greatest capacity to accept cholesterol from cholesterol-laden 
macrophages are at greatest prospective risk for myocardial infarction, stroke, or death. Further development and characterization of 
high-density lipoprotein functional measures and their relationship with incident cardiovascular event risks are needed.
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Supplemental Figure I 
Recovery of ApoA1, ApoA2, albumin, ApoB, PON1, HDL cholesterol and Lp(a)
after serum ApoB-depletion.
Serum samples from the outpatient cohort were treated with PEG 6000 to form 
ApoB-depleted serum as described under Methods. For ApoA1, ApoA2, albumin, 
ApoB, PON 1 and HDL cholesterol, data shown are from 20 random individual 
sera before and after ApoB-depletion. For Lp(a), 12 individual sera from the 
angiographic cohort with elevated Lp(a) levels ranging from 35 to 133 mg/dL 
were used, and Lp(a) levels were measured before and after PEG treatment.
Results shown represent mean +/- SD. 
Supplemental Figure II 
Western-blot of load, flow through, wash and elution of immunoprecititation of 
ApoA1 from lipoprotein-deficient medium and quantitative ApoA1 recovery. 
In this study we sought to confirm quantitative recovery of ApoA1 under the 
conditions employed to determine the amount of radiolabeled-cholesterol
associated with ApoA1. Briefly, media used in cholesterol efflux activity studies 
was first separated by buoyant density centrifugation into various lipoprotein 
fractions vs. the lipoprotein depleted media (LPDM, d>1.21). The LPDM was then 
mixed with a cocktail of monoclonal antibodies specific to ApoA1 as described 
under Methods. Following brief incubation, this mixture was then applied to an 
immobilized Protein A resin column. The flow through fraction, wash and eluted 
fraction were collected, volumes measured, and both radiolabeled cholesterol, 
and the abundance of ApoA1 within each fraction determined. Shown above are 
the Western blot analyses of the indicated fractions analyzed by SDS PAGE 
using antibody specific for ApoA1. The calculated % recovery of ApoA1 from the 
starting material (100% loading) is indicated on the Figure. Note that 97% of the 
ApoA1 was removed from the starting (load) material, and 95% of the ApoA1 
was recovered in the eluted fraction under the conditions employed to determine 
the proportion of cholesterol bound to ApoA1 during the cholesterol efflux 
studies.
Supplemental Figure III 
SDS-PAGE of load, flow through, wash and elution of immunoprecipitation of 
albumin from lipoprotein-deficient medium and quantitative albumin recovery. 
In this study we sought to confirm quantitative recovery of albumin under the 
conditions employed to determine the amount of radiolabeled-cholesterol
associated with albumin. Briefly, lipoprotein depleted media from cholesterol 
efflux activity studies was mixed with a cocktail of polyclonal antibodies specific 
to human albumin as described under Methods. This mixture was then applied to 
an immobilized Protein A/G resin column. The flow through fraction, wash and 
eluted fraction were collected, volumes measured, and both radiolabeled 
cholesterol, and albumin abundance within each fraction determined. Shown 
above are the analyses of the indicated fractions analyzed by SDS PAGE. The 
calculated % recovery of albumin from the starting material (100% loading) is 
indicated on the Figure. Note that 95% of the albumin was removed from the 
starting (load) material, and 90% of the albumin was recovered in the eluted 
fraction under the conditions employed to determine the proportion of cholesterol 
bound to albumin (or albumin associated protein(s)) during the cholesterol efflux 
studies.
Supplemental Figure IV 
SDS-PAGE of various sources of albumin (listed left to right from the Marker 
lane) including Bovine Serum Albumin (BSA) (Sigma), Human Serum Albumin 
(HSA) (Sigma), FPLC isolated HSA and FPLC isolated and delipidated HSA.
Each sample lane was loaded with 5 ?g protein. 
The purity of HSA and BSA were assessed from the indicated sources by 
analyzing comparable amounts of protein per lane fractionated by SDS PAGE 
and detected with Coomassie Blue staining. Human albumin (FPLC isolated +/- 
delipidation) was isolated as described under Methods.
Supplemental Figure V 
Comparison of ApoB-depleted serum cholesterol efflux activity from RAW 
264.7 cells and J774A.1 cells. Cellular cholesterol efflux assays were 
performed under conditions of ABCA1 stimulation as described in Methods using 
murine macrophage RAW 264.7 cells and J774A.1 cells for direct head-to-head 
comparisons.  For these studies, serum was used from a random sampling of 
subjects with documented CAD (n=36) and subjects without known CAD (n=27) 
to determine whether comparable efflux activity results were observed among 
both disease and non-disease subjects.  All data points represent duplicate 
experiments.  R = Spearman correlation coefficient. 
Supplemental Figure VI 
Inter-batch ApoB-depleted serum total cholesterol efflux assay 
reproducibility. Pools of serum representing low, medium and high HDL-c levels 
were used in ABCA1 stimulated cholesterol efflux assays as described in 
Methods.  Data points represent at least triplicate determinations. Results were 
plotted as month-month variability. R = Spearman correlation coefficient.
Supplemental Figure VII 
Odds ratios for prevalent coronary artery disease risk, and hazard ratios 
for incident major adverse cardiovascular risk according to cholesterol 
efflux activity. ApoB depleted serum from subjects in the Stable Angiographic 
Cohort were assayed for cholesterol efflux activity using ApoB-depleted serum as 
cholesterol acceptor. Coronary artery disease (CAD); Results (n=1150) were fit 
to a multiple logistic regression model with DM, HTN, smoking, LDLc, HDLc, age, 
gender, total efflux. Major adverse cardiac events within 3 years (MACE3); 
Results were fit to a Cox model with DM, HTN, smoking, LDL, HDL, age, gender, 
total efflux. The 5-95% confidence interval is indicated by line length. 
Supplemental Figure VIII 
Direct comparison of total cholesterol efflux activity between RAW264.7 
and J774A.1 cell lines.  Cellular cholesterol efflux activity was measured under 
conditions of ABCA1 stimulation as described in Methods using either murine 
macrophage RAW 264.7 cells or J774A.1 cells for direct comparisions. For these 
studies, ApoB-depleted serum was used from a set of 80 random subjects. Each 
point represents the mean and range of replicate determinations for each cell 
type.
Supplemental Figure VIIII 
Direct comparison of cAMP-independent cholesterol efflux activity between 
RAW264.7 and J774A.1 cell lines.  Cellular cholesterol efflux activity was 
measured in the presence vs absence of ABCA1 stimulation as described in 
Methods using either murine macrophage RAW 264.7 cells or J774A.1 cells for 
direct comparisions.  ABCA1-independent cholesterol efflux activity is shown. For 
these studies, ApoB-depleted serum was used from a set of 80 random subjects. 
Each point represents the mean and range of replicate determinations for  each 
cell type. 
Supplemental Table I 
HDL related parameters for sera used to quantify radiolabel cholesterol
distribution in efflux assay 
HDLc
( mg/dL) 
ApoA1
( mg/dL) 
LDLc
( mg/dL) 
Total
cholesterol
( mg/dL) 
Pooled sera  A 67.4 173.0 119.0 200.2 
Pooled sera B 59.3 156.1 104.0 180.9 
Pooled sera C 56.8 151.8 111.0 186.5 
Pooled sera  D 61.4 163.3 111.0 193.0 
These 4 sera pools represent data from pooled sera from multiple apparently 
healthy volunteer subjects, each pool comprised of ~5 units of serum. They were 
used to monitor the lipoprotein compartments into which radiolabeled cholesterol 
partitions during the cellular cholesterol efflux activity assay and were also used 
as controls during efflux activity assays. These were aliquoted and were used 
after single thaw in every efflux assay performed in this report to ensure 
consistency. Their HDLc, ApoA1, LDLc and total cholesterol levels were similar 
to that of the healthy control subjects described in the outpatient cohort. HDLc, 
ApoA1, LDLc and total cholesterol concentrations were determined as described 
in Methods. 
.
Supplemental Table II 
 Comparison of percentage distribution of ApoA1 in the fraction of HDL 
(1.063<d<1.21) and the fraction having d>1.21 with versus without PEG. 
 HDL ( control) HDL+PEG 
ApoA1 in HDL (%)
( 1.063<d<1.21) 
87.7 ± 0.2 89.2 ± 0.2 
ApoA1 in d>1.21 (%) 12.3 ± 0.2 10.8 ± 0.2 
Samples were processed and ApoA1 determined as described in Methods.
Supplemental Table III 
Predicated cholesterol efflux acceptor activity and contribution in serum by 
ApoA1 and albumin based upon specific activity of cholesterol efflux activity and 
normal circulating concentrations
Specific activity of 
cholesterol efflux 
[%/(mg/ml) /15 hrs]
serum
concentration
(mg/ml)
Predicted total 
cholesterol efflux 
activity in serum 
(% /15 hrs) 
% contribution to 
total predicted 
cholesterol efflux 
activity in serum 
ApoA1 2075.0 1.5 3112.5 90.4
Albumin 7.3 45.0 329.0 9.6
Fold ApoA1  is 284 fold 
better cholesterol 
acceptor than 
albumin
Albumin is 
30-fold more
abundant
than ApoA1 
At normal serum 
levels, albumin is 
predicted to 
account for ~1/10th
as much 
cholesterol
acceptor activity as 
ApoA1
Supplemental Table IV 
Correlation Coefficients between HDL/Lipoproteins-Related Variables and ApoB-
depleted Serum Total Cholesterol Efflux 
?Outpatient?and?Healthy?
Volunteer??Cohort?
?Angiographic?cohort?Variable?
Non?CAD?
?(?N=431)?
CAD????
(?N=146)?
Non?CAD???
(?N=279)??
CAD????
?(?N=871)?
MI/Stroke?
(N=58)?
MACE?
(N=113)?
HDLc? 0.55?
(p<0.001)?
0.31?
(p<0.001)?
0.55?
(p<0.001)?
0.41?
(p<0.001)?
0.3?
(p=0.023)?
0.42?
(p<0.001)?
ApoA1? 0.63?
(p<0.001)?
0.43?
(p<0.001)?
0.58?
(p<0.001)?
0.55?
(p<0.001)?
0.53?
(p<0.001)?
0.62?
(p<0.001)?
ApoA2? 0.47?
(p<0.001)?
0.55?
(p<0.001)?
0.49?
(p<0.001)?
0.45?
(p<0.001)?
0.46?
(p<0.001)?
0.53?
(p<0.001)?
Albumin? ?0.05?
(p=0.322)?
0.19?
(p=0.064)?
0.05?
(p=0.394)?
0.07?
(p=0.06)?
?0.08?
(p=0.54)?
0.07?
(p=0.457)?
?????????????? ???????
??????????????????????????????????????????????????????? ????????????????????????????????????????????
????????????????? ????? ???????????? ??? ????????? ??????????????????????????????????? ??????? ???????
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General Procedures
ApoB-depleted serum was prepared by addition of PEG 6000 using 
methods similar to that previously described Rothblat and colleagues1, 2.   Briefly, 
40 parts 20% PEG 6000 (QIAGEN Science, Germantown, MD) was added to 
100 parts serum with gentle mixing, and then incubated at room temperature for 
20 minutes. ApoB-depleted serum was then obtained by recovery of supernatant 
following centrifugation (10,000 rpm, 30 minutes, 4?C). Apolipoproteins, 
lipoprotein a (Lp(a)), albumin, complete lipid profiles (including direct LDL 
cholesterol determinations) and cardiac troponin I levels were determined using 
the Abbott Architect platform (Abbott Diagnostics, Chicago, Illinois). All lipid and 
lipoprotein measurements employed FDA-cleared in vitro diagnostic assays, and 
were performed in a CAP accredited and CLIA licensed laboratory that also 
annually participates in the CDC lipid standardization program.  VLDL 
(1.006<d<1.019 g/ml fraction), LDL (1.019<d<1.063 g/ml fraction) and HDL 
(1.063<d<1.21 g/ml fraction) were isolated from plasma, serum or tissue culture 
media by sequential buoyant density ultracentrifugation using sucrose and D2O 
to avoid high ionic strength associated alterations to protein compositions of 
lipoprotein particles observed with KBr use3. The fraction remaining following 
removal (floatation) of lipoproteins was called "lipoprotein-depleted" (LPD) 
(d>1.21 g/ml). Fast protein liquid chromatography (FPLC)-based isolation of 
human albumin was purified from fresh lipoprotein-depleted plasma by ion 
exchange chromatography using Q-SepharoseTM XL resin ( GE Healthcare, 
Uppsala, Sweden) with discontinuous salt gradient, and delipidation performed 
using methanol:ether:chloroform as described4. The purity of FPLC isolated 
albumin was characterized by SDS-PAGE and scanning densitometry of 
Coomassie Blue stained gel, which showed >98% purity. Protein content was 
determined by the Markwell-modified Lowry protein assay5. Paraoxonase activity 
measures were performed as recently described6. 
Cellular Cholesterol Efflux Activity Assays 
Cholesterol efflux activity assays were performed essentially as recently 
described by Khera et al7 except for a key change that radiolabeling counts were 
monitored within both cell compartment and media for every sample (i.e. not just 
within media and a handful of control samples for cell pellet). All assays 
employed radiolabeled free cholesterol enriched cultured macrophages under 
conditions that have nominal cholesterol ester (CE) labeling (similar to that in7), 
and the procedures employed were similar to those previously described8, but 
adapted for high-throughput screening. Briefly, macrophages (typically 
RAW264.7; ATCC,Rockville, MD; though other macrophage cell lines as outlined 
below were also employed) in 48- or 96-well plates were first plated, cultured and 
loaded with 0.2 ?Ci/ml radiolabeled cholesterol (either [3H]-cholesterol (47.9 
Ci/mmol, Perkin Elmer, Boston, MA) or [14C]-cholesterol (50 mCi/mmol, American 
Radiolabeled Chemicals, St Louis, MO) in Dulbecco's modified Eagle's medium 
(DMEM) (tissue culture core facility, Lerner Research Institute, Cleveland, OH) 
for 24 hours at 37?C.  The day after labeling, the cells were washed with 
phosphate buffered saline, and then incubated in DGGB (DMEM supplemented 
with 50 mM glucose, 2 mM glutamine, 0.2% BSA and 1% penicillin-streptomycin) 
with (to induce ABCA1) or without 0.3 mM (final) 8-Br-cAMP(Sigma-Aldrich, St 
Louis, MO) for 24 hours.  Efflux to cholesterol acceptor (2%, v/v, ApoB-depleted 
serum unless otherwise indicated) was measured after an additional 4 hours of 
incubation in the presence of 8-Br-cAMP, with recovered media either briefly 
centrifuged or passed through a glass filter to ensure removal of all potential 
cellular debris. All efflux assays were performed with at least duplicate 
determinations. Where indicated, instead of murine macrophage RAW 264.7 
cells, J774A.1 (ATCC, Rockville MD) cells were used in RPMI media (tissue 
culture core facility, Lerner Research Institute, Cleveland, OH). Separate one 
time use aliquots from three different pools of sera (healthy controls with low 
normal, mid and high HDLc levels) were included on each plate to allow for 
monitoring of plate to plate and day to day variations. Overall intra- and inter-
plate coefficients of variation were excellent, with 3.1-4.5% intra-batch, and 7.6-
11.4% (depending on low, mid versus high HDLc control) inter-batch CVs 
throughout the duration of analyses of all study samples. The relative cholesterol 
efflux activity was calculated for each sample as the radioactivity in the medium 
divided by total radioactivity (medium plus cell extracted from hexane/ 
isopropanol) in sample.  
Immuno-precipitation of ApoA1 and albumin in lipoprotein-depleted media. 
Lipoprotein-depleted media (d>1.21 g/ml) recovered from cholesterol 
efflux activity measures was first mixed with a cocktail of mouse anti-human 
ApoA1 monoclonal antibodies (homemade monoclonal antibodies 2D10.5, 
4G11.2, 2H7, 6C8.1, 5H8.1, and 10G1.5, and a commercial mouse anti-human 
ApoA1 mAb from BIODESIGN International) and then total IgG and IgG:ApoA1 
complexes were quantitatively removed using immobilized protein A (Pierce, 
Rockford, IL). Quantitative removal of ApoA1 was independently confirmed by 
SDS-PAGE followed by Western blot analyses and scanning densitometry with 
ApoA1 levels titrated in separate lanes for generating standard curve. Under the 
conditions employed, 97% removal of ApoA1 from starting material/media, and 
95% recovery in the eluted fraction was documented. Immunoprecipitation of 
human albumin in lipoprotein-depleted media was similarly performed by first 
adding purified anti-human albumin polyclonal antibody (Thermo Scientific, 
Rockford, IL, catalog number PA1-65133), incubation, followed by removal with 
protein A/G resin (Thermo Scientific, Rockford, IL). Analyses revealed albumin 
removal (via immuno-precipitation) was near complete (~95% removed) with 
overall recovery in eluted fractions being ~90%. For both ApoA1 and albumin 
immuno-precipitation studies, parallel experiments employing non-specific 
isotype control IgG antibodies were employed and revealed non-specific binding 
to resins was negligible (<2%) under the conditions employed. Radiolabeled 
cholesterol before and following ApoA1 and albumin removal were quantified by 
liquid scintillation counting using a Beckman Scintillation Counter (Fullerton, CA). 
Quantification of radiolabel in free vs. esterified cholesterol cellular pools.   
The proportion of radiolabeled cholesterol in the cholesteryl ester (CE) 
versus free cholesterol pools of cholesterol-enriched macrophages was 
measured by first recovering radiolabeled sterols from cell pellets with sequential 
(x 3) hexane/ isopropanol (3/2, v/v) extractions. The combined organic extracts 
were dried under nitrogen, resuspended in chloroform/methanol (2/1, v/v), and 
organic extracts spotted onto silica gel plates with preadsorbent strip (GE Life 
Sciences, Piscataway, NJ). After brief drying of solvents with cool air using a hair 
dryer, the thin layer chromatography plates were developed using hexane:diethyl 
ether:acetic acid (70:30:1, v/v/v) in saturated tanks. The bands corresponding to 
free cholesterol and CE were identified, scraped into vials, and radiolabel sterol 
in each fraction quantified by liquid scintillation.  
Study populations.   
Serum samples and associated clinical data were collected from two 
distinctively different populations, each of which were divided into a case:control 
cohort based upon clinical evidence of CAD. CAD in all subjects was defined by 
a clinical history of documented CAD, documented history of prior 
revascularization, or history of MI confirmed by angiography records, EKG or 
cardiac enzyme testing. For subjects in the angiographic cohort (see below), 
CAD was also defined angiographically by ?50% stenosis in one or more major 
coronary vessels.  All subjects studied gave written informed consent approved 
by the Cleveland Clinic Institutional Review Board.  The first cohort (Cohort A – 
Angiographic Cohort; N=1150) was comprised of sequential participants enrolled 
in the study GeneBank9-13, which consists of sequential stable subjects without 
evidence of acute coronary syndrome (cardiac troponin I <0.03 ng/mL) who 
underwent elective diagnostic coronary angiography (cardiac catheterization or 
coronary computed tomography) for evaluation of CAD. All subjects had 
extensive clinical and longitudinal outcomes data monitored, including 
adjudicated outcomes over the ensuing 3 years for all participants after 
enrollment. Major adverse cardiovascular event (MACE) was defined as death, 
nonfatal MI, or nonfatal cerebrovascular accident (stroke) following enrollment. 
The second cohort (Cohort B – Outpatient Cohort; n=577) was comprised of 
sequential consenting subjects undergoing cardiac risk factor 
evaluation/modification in an outpatient preventive cardiology clinic at the 
Cleveland Clinic11, 14, as well as sequential consenting volunteers undergoing 
health screenings that included demographics/medical history collection, physical 
examination and blood laboratory testing. Serum samples were collected in all 
subjects using serum separator vacutainer tubes. Whole blood was allowed to 
clot at room temperature for 60 min, and then immediately placed into ice/water 
bath until processing. For all samples (both cohorts), serum was isolated and 
aliquots were frozen into cryovials at -80°C within 4 hours of time of blood draw. 
Healthy volunteers provided serum that was pooled (at least n>5 units per pool) 
and used as controls during efflux activity assays. Sera pools from healthy 
volunteers were also used to monitor the lipoprotein compartments into which 
radiolabeled cholesterol partitions during the cellular cholesterol efflux activity 
assay. For these latter studies, all sera used showed normal range HDLc (>45 
mg/dL) and ApoA1 (>150 mg/dL). For studies assessing the efficiency of PEG 
depletion of Lp(a), a dozen samples from subjects in the angiographic cohort with 
identified Lp(a) levels in excess of 30 mg/dL and as high as 133 mg/dL were 
used. 
Statistical Analyses.   
Variables are expressed as mean ± standard deviation or median 
(interquartile ranges [IQR]).  Spearman’s correlation was used to determine 
association between cholesterol efflux activities and fasting lipids/lipoproteins 
and cardiovascular phenotypes.  The main outcome measure is the association 
of cholesterol efflux activity (using ApoB-depleted serum as cholesterol acceptor) 
with prevalent CAD and prospective MACE at 3 years follow-up. Odds ratio (OR) 
for prevalent CAD and corresponding 95% confidence intervals (CI) were 
calculated using both univariate (unadjusted) and multivariate (adjusted) logistic 
regression models.  Hazard ratio (HR) for adverse incident cardiovascular events 
(death, MI, stroke) and corresponding 95% CI were estimated using both 
univariate (unadjusted) and multivariate (adjusted) Cox models.  Adjustments 
were made for individual traditional cardiac risk factors (including age, gender, 
diabetes mellitus, hypertension, cigarette smoking, HDLc, low-density lipoprotein 
cholesterol).  All analyses were performed using R 2.13.1 (Vienna, Austria) and 
p-values <0.05 were considered statistically significant.
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